Greg Mirigian is the Vice President of Product Development at JenaValve Technology, a pioneer in the design and manufacture of Transcatheter Heart Valves for aortic regurgitation. Over the past 8 years, he has led R&D toward CE Mark approval of the Trilogy Transcatheter Heart Valve System and the successful completion of the ALIGN-AR clinical trial in the United States. Prior to joining JenaValve, he was Chief Technology Officer for INCUMEDx, a medical device incubator and previously held various leadership roles over 16 years at Boston Scientific in the neurovascular and vascular divisions. Greg holds a Bachelor of Science in Mechanical Engineering and a Business Minor from San Jose State University.